DE60222745D1 - Verwendung von neurofilamentproteinen zur behandlung von tumoren - Google Patents

Verwendung von neurofilamentproteinen zur behandlung von tumoren

Info

Publication number
DE60222745D1
DE60222745D1 DE60222745T DE60222745T DE60222745D1 DE 60222745 D1 DE60222745 D1 DE 60222745D1 DE 60222745 T DE60222745 T DE 60222745T DE 60222745 T DE60222745 T DE 60222745T DE 60222745 D1 DE60222745 D1 DE 60222745D1
Authority
DE
Germany
Prior art keywords
tumors
treatment
neurofilament proteins
proteins
neurofilament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60222745T
Other languages
English (en)
Other versions
DE60222745T2 (de
Inventor
Paul Averback
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nymox Pharmaceutical Corp Canada
Original Assignee
Nymox Pharmaceutical Corp Canada
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nymox Pharmaceutical Corp Canada filed Critical Nymox Pharmaceutical Corp Canada
Publication of DE60222745D1 publication Critical patent/DE60222745D1/de
Application granted granted Critical
Publication of DE60222745T2 publication Critical patent/DE60222745T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
DE60222745T 2001-03-08 2002-03-08 Verwendung von neurofilamentproteinen zur behandlung von tumoren Expired - Lifetime DE60222745T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27395701P 2001-03-08 2001-03-08
US273957P 2001-03-08
PCT/IB2002/001959 WO2002074323A2 (en) 2001-03-08 2002-03-08 Using neural thread proteins to treat tumors and other hyperproliferative disorders

Publications (2)

Publication Number Publication Date
DE60222745D1 true DE60222745D1 (de) 2007-11-15
DE60222745T2 DE60222745T2 (de) 2008-07-10

Family

ID=23046145

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60222745T Expired - Lifetime DE60222745T2 (de) 2001-03-08 2002-03-08 Verwendung von neurofilamentproteinen zur behandlung von tumoren

Country Status (15)

Country Link
US (1) US20030054990A1 (de)
EP (2) EP1857115A3 (de)
JP (1) JP2004529908A (de)
KR (1) KR100632903B1 (de)
CN (1) CN1529613A (de)
AT (1) ATE374619T1 (de)
AU (1) AU2002304314B2 (de)
BR (1) BR0207638A (de)
CA (1) CA2439757A1 (de)
CY (1) CY1109650T1 (de)
DE (1) DE60222745T2 (de)
DK (1) DK1368054T3 (de)
ES (1) ES2295347T3 (de)
PT (1) PT1368054E (de)
WO (1) WO2002074323A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1387698B1 (de) * 2001-05-04 2007-11-14 Nymox Corporation Verfahren zur vorbeugung von zelltod unter verwendung von antikörpern gegen neural thread proteine
EP1541166B1 (de) * 2001-05-16 2007-12-19 Nymox Corporation Prävention des Zelltodes durch Verwendung von Segmenten der Neurofilamentproteinen
DE60224231D1 (de) 2001-05-16 2008-01-31 Nymox Corp Prävention des Zelltodes durch Verwendung von Segmenten der Neurofilamentproteinen
NZ529911A (en) 2001-05-25 2008-05-30 Nymox Corp Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
US7544771B2 (en) * 2005-02-23 2009-06-09 Nymox Corporation Protein and its use in diagnosing Alzheimer's disease
US8211450B2 (en) 2010-05-05 2012-07-03 Senju Usa, Inc. Ophthalmic composition
US9642687B2 (en) 2010-06-15 2017-05-09 The Procter & Gamble Company Methods for whitening teeth
WO2011159829A2 (en) * 2010-06-15 2011-12-22 Old Dominion University Research Foundation Method and device for treatment of conditions aggravated by amyloid fibrils
US20160361380A1 (en) 2015-06-12 2016-12-15 Nymox Corporation Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations
US11628202B2 (en) 2015-07-24 2023-04-18 Nymox Corporation Methods of reducing the need for surgery in patients suffering from benign prostatic hyperplasia
US10183058B2 (en) 2016-06-17 2019-01-22 Nymox Corporation Method of preventing or reducing the progression of prostate cancer
US10172910B2 (en) 2016-07-28 2019-01-08 Nymox Corporation Method of preventing or reducing the incidence of acute urinary retention
US10532081B2 (en) 2016-09-07 2020-01-14 Nymox Corporation Method of ameliorating or preventing the worsening or the progression of symptoms of BPH
US10335453B2 (en) 2017-03-01 2019-07-02 Nymox Corporation Compositions and methods for improving sexual function
CN108341854B (zh) * 2018-02-09 2020-02-18 中国医科大学 一种肿瘤靶向的新型多肽及其用途
US20200061150A1 (en) 2018-08-23 2020-02-27 Nymox Corporation Method of inducing selective prostate glandular pharmaco-ablation with sparing of nerves and preservation of sexual function
US11298400B2 (en) 2019-05-13 2022-04-12 Nymox Corporation Method of enhancing the therapeutic efficacy of fexapotide triflutate in treating LUTS
US11278588B2 (en) 2019-05-13 2022-03-22 Nymox Corporation Method of treating lower urinary tract symptoms with fexapotide triflutate
US11331374B2 (en) 2019-07-31 2022-05-17 Nymox Corporation Focal treatment of prostate cancer
US11231421B2 (en) 2019-07-31 2022-01-25 Nymox Corporation Methods of treating multifocal cancer

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL93018C (de) * 1957-10-22
JPS5936174A (ja) * 1982-08-23 1984-02-28 Ricoh Co Ltd インクジエツト記録用水性インク
JPS59106989A (ja) * 1982-12-10 1984-06-20 Ricoh Co Ltd インクジエツト記録法
US4588998A (en) * 1983-07-27 1986-05-13 Ricoh Company, Ltd. Ink jet head having curved ink
US4994110A (en) * 1986-08-27 1991-02-19 Hewlett-Packard Company Dyes containing lithium for ink-jet printing inks
US5231170A (en) * 1986-08-27 1993-07-27 Paul Averback Antibodies to dense microspheres
US4874779A (en) * 1988-06-29 1989-10-17 Bristol-Myers Company Mitomycin phosphate derivatives
CA2006332C (en) * 1988-12-21 2003-04-08 Suzanne De La Monte Method of detecting neurological disease or dysfunction
US5948634A (en) * 1988-12-21 1999-09-07 The General Hospital Coporation Neural thread protein gene expression and detection of alzheimer's disease
US5462592A (en) * 1992-06-09 1995-10-31 Ricoh Company, Ltd. Aqueous ink composition
JP3176444B2 (ja) * 1992-10-01 2001-06-18 株式会社リコー 水性インク及びこれを用いた記録方法
JP3247784B2 (ja) * 1993-12-22 2002-01-21 株式会社リコー 水性インク及びこれを用いた記録方法
JP2888166B2 (ja) * 1995-04-04 1999-05-10 富士ゼロックス株式会社 インクジェット記録用インクおよびインクジェット記録方法
JP3620097B2 (ja) * 1995-04-28 2005-02-16 株式会社リコー 水性インク
JP3350839B2 (ja) * 1995-05-30 2002-11-25 株式会社リコー インクジェット記録用イエローインク及び画像記録方法
US5637138A (en) * 1995-06-06 1997-06-10 Brother Kogyo Kabushiki Kaisha Ink composition, process for its preparation, and ink-jet recording process
JP3475249B2 (ja) * 1996-07-25 2003-12-08 株式会社リコー 記録液及びそれを用いた記録方法
US5879439A (en) * 1996-08-01 1999-03-09 Ricoh Company, Ltd. Recording ink composition and recording method using the same
US6620922B1 (en) * 1997-02-25 2003-09-16 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
JP3583257B2 (ja) * 1997-03-17 2004-11-04 株式会社リコー 画像記録法及び画像記録装置並びに画像記録促進液
US6120589A (en) * 1998-02-20 2000-09-19 Ricoh Company, Ltd. Set of color ink compositions for ink-jet printing and method of forming color images using the color ink set
US6273985B1 (en) * 1998-06-26 2001-08-14 Xerox Corporation Bonding process
US6613136B1 (en) * 1999-09-17 2003-09-02 Ricoh Company, Ltd. Recording ink composition and ink-jet printing method using the same
CN1300779A (zh) * 1999-12-22 2001-06-27 上海博德基因开发有限公司 一种新的多肽－人神经元线蛋白17和编码这种多肽的多核苷酸
CN1300778A (zh) * 1999-12-22 2001-06-27 上海博德基因开发有限公司 一种新的多肽－人神经元线蛋白15和编码这种多肽的多核苷酸
US6730155B2 (en) * 2000-06-30 2004-05-04 Ricoh Company, Ltd. Aqueous ink composition
JP3874336B2 (ja) * 2000-12-05 2007-01-31 株式会社リコー 記録液、これを用いたインクジェット記録方法及び記録用機器
US6730149B2 (en) * 2001-01-22 2004-05-04 Ricoh Company Limited Ink composition and inkjet recording method and apparatus using the ink composition
JP2002285047A (ja) * 2001-03-23 2002-10-03 Ricoh Co Ltd 水性記録液、該液を用いた記録方法および機器
NZ529911A (en) * 2001-05-25 2008-05-30 Nymox Corp Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
BR0211199A (pt) * 2001-07-19 2004-10-26 Nymox Corp Peptìdeos efetivos no tratamento de tumores e outras condições que requerem a remoção ou destruição de células

Also Published As

Publication number Publication date
EP1857115A2 (de) 2007-11-21
US20030054990A1 (en) 2003-03-20
WO2002074323A3 (en) 2003-10-02
CY1109650T1 (el) 2014-08-13
EP1857115A3 (de) 2008-08-06
CN1529613A (zh) 2004-09-15
EP1368054A2 (de) 2003-12-10
CA2439757A1 (en) 2002-09-26
JP2004529908A (ja) 2004-09-30
KR20040000403A (ko) 2004-01-03
PT1368054E (pt) 2008-01-10
KR100632903B1 (ko) 2006-10-13
WO2002074323A2 (en) 2002-09-26
EP1368054B1 (de) 2007-10-03
DE60222745T2 (de) 2008-07-10
DK1368054T3 (da) 2008-02-04
ATE374619T1 (de) 2007-10-15
BR0207638A (pt) 2004-07-27
AU2002304314B2 (en) 2007-09-06
ES2295347T3 (es) 2008-04-16

Similar Documents

Publication Publication Date Title
CY1109650T1 (el) Χρηση νευρικων νηματικων πρωτεϊνων για την αντιμετωπιση νεοπλασιων
BRPI0213786B8 (pt) peptídeos efetivos no tratamento de tumores e outras condições que requerem a remoção ou destruição de células
CY1111120T1 (el) Πεπτιδια που παραγονται απο πρωτεϊνες νευρικων ινων και η ιατρικη τους χρηση
WO2003008443A3 (en) Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
DE69921156D1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
DE50212701D1 (de) Bestrahlungsanordnung zur behandlung von akne und aknenarben
ATE415962T1 (de) Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
ATE249220T1 (de) Verwendung von piperin und derivate davon zur behandlung von hautpigmentierungstörungen und hautkrebs
DE602004007942D1 (de) Chemische aktivierung und veredelung von südkieferkraftfasern
DE60031951D1 (de) Methoden zur verwendung von neurotrophin 3 (nt-3) zur behandlung von gastrointestinalen hypomobilitätsstörungen
DE60218153D1 (de) Verwendung von proteasom-inhibitoren zur behandlung des trockenen auges
DE58907851D1 (de) Verwendung von dimethylpolysiloxan zur behandlung von erkrankungen des gastrointestinaltraktes.
DE69827387D1 (de) Verwendung von pramipexol zur behandlung von restless-legs-syndrom
ATE419851T1 (de) Verwendung von riluzol zur behandlung multipler sklerose
DE60033569D1 (de) Neue verwendung von prodigiosin zur behandlung von diabetes mellitus
ATE291434T1 (de) Verwendung von angiotensin zur behandlung von krebsmetastasierung
DE69711422D1 (de) Verwendung von (r)-verapamil als medizin zur behandlung von angina
ATE288263T1 (de) Verwendung von n-oleoylethanolamin zur behandlung der schuppenflechte (psoriasis)
DE60213968D1 (de) Blutgerinnungsfaktor xiii zur behandlung von plättchenfunktionsstörungen
DE60022317D1 (de) Verwendung von fluorierten triazolen zur behandlung von neuropathischem schmerz

Legal Events

Date Code Title Description
8364 No opposition during term of opposition